Mechanistically, Alivec binds tropomyosin 3 (Tpm3) and heterogeneous nuclear ribonucleoprotein A2/B1 (Hnrnpa2b1) to regulate chondrogenic transformation of VSMCs implicated in vascular dysfunction and hypertension. Here, HNRNPA2B1 is linked to hypertensive disorder.